MCID: DDN010
MIFTS: 52

Duodenum Cancer

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Duodenum Cancer

MalaCards integrated aliases for Duodenum Cancer:

Name: Duodenum Cancer 12 15
Duodenal Cancer 12 6 70
Duodenal Neoplasms 44 70
Malignant Neoplasm of Duodenum 70
Cancer of Duodenum 12
Duodenal Carcinoma 54
Duodenal Neoplasm 12
Cancer, Duodenal 39

Classifications:



External Ids:

Disease Ontology 12 DOID:10021
ICD9CM 34 152.0
MeSH 44 D004379
NCIt 50 C4803 C9328
SNOMED-CT 67 254570009 363403002
ICD10 32 C17.0
UMLS 70 C0013291 C0153426 C0541912

Summaries for Duodenum Cancer

Disease Ontology : 12 A small intestine cancer that is located in the beginning section of the small intestine.

MalaCards based summary : Duodenum Cancer, also known as duodenal cancer, is related to tubular adenocarcinoma and ampulla of vater cancer, and has symptoms including abdominal pain An important gene associated with Duodenum Cancer is KRT7 (Keratin 7), and among its related pathways/superpathways are TCR Signaling (Qiagen) and Endometrial cancer. The drugs Celecoxib and Ursodeoxycholic acid have been mentioned in the context of this disorder. Affiliated tissues include beginning section of the small intestine, small intestine and pancreas, and related phenotypes are Reduced mammosphere formation and Synthetic lethal with MLN4924 (a NAE inhibitor)

Wikipedia : 73 Duodenal cancer is a cancer in the first section of the small intestine known as the duodenum. Cancer of... more...

Related Diseases for Duodenum Cancer

Diseases related to Duodenum Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 499)
# Related Disease Score Top Affiliating Genes
1 tubular adenocarcinoma 30.4 MUC5AC MUC1 KRT7 CEACAM5 CDX2
2 ampulla of vater cancer 30.3 TP53 SMAD4 MUC6 MUC5AC MUC1 MIR196A1
3 intestinal obstruction 30.2 KRT7 CEACAM5 CDX2
4 duodenal obstruction 30.2 SCT CEACAM5
5 somatostatinoma 30.2 SST MEN1 GAST
6 neuroendocrine tumor 30.2 SST SCT MEN1 HRAS GAST CDX2
7 zollinger-ellison syndrome 30.1 SST SCT MEN1 GAST
8 duodenal ulcer 30.0 SST SCT GAST
9 peutz-jeghers syndrome 29.9 TP53 SMAD4 MUC6
10 gastric ulcer 29.8 TP53 SST GAST
11 duodenum adenocarcinoma 29.8 PMS2 MUC6 MUC5AC MSH6 MSH2 MLH1
12 penile cancer 29.8 TP53 KRAS HRAS
13 neuroendocrine carcinoma 29.8 SST MUC1 MEN1 KRT7 GAST CEACAM5
14 in situ carcinoma 29.7 TP53 MUC1 HRAS
15 keratoacanthoma 29.6 TP53 MSH2 MLH1
16 gastrointestinal carcinoma 29.6 TP53 MUC1 GAST CEACAM5 CDX2
17 pancreatic adenocarcinoma 29.5 TP53 SMAD4 KRAS HRAS
18 atrophic gastritis 29.4 TP53 SST MUC6 MEN1 GAST CDX2
19 gallbladder cancer 29.4 TP53 MLH1 KRAS CEACAM5 CDX2
20 ovarian mucinous neoplasm 29.4 MUC6 MUC5AC KRT7 KRAS HRAS CEACAM5
21 sarcoma 29.4 TP53 MUC1 MSH2 KRAS HRAS
22 gastritis 29.4 TP53 SST SCT MUC6 GAST CDX2
23 familial adenomatous polyposis 29.4 TP53 SMAD4 MUTYH MSH6 MSH2 MLH1
24 lynch syndrome i 29.4 PMS2 MSH6 MSH2 MLH1
25 neurofibromatosis 29.3 PMS2 MSH6 MSH2 MLH1 KRAS HRAS
26 peptic ulcer disease 29.2 TP53 SST SCT MUC5AC MEN1 HRAS
27 barrett esophagus 29.1 TP53 SMAD4 MUC6 MUC5AC MIR196A1 KRT7
28 microinvasive gastric cancer 28.9 TP53 MUC6 MUC5AC MLH1 MIR196A1 GAST
29 villous adenoma 28.7 TP53 SST MUC6 MUC5AC MUC1 MLH1
30 muir-torre syndrome 28.6 TP53 PMS2 MUTYH MSH6 MSH2 MLH1
31 esophageal cancer 28.6 TP53 SMAD4 MUC1 MLH1 MIR196A1 KRAS
32 cowden syndrome 1 28.5 TP53 SMAD4 PMS2 MUTYH MSH6 MSH2
33 lung cancer susceptibility 3 28.4 TP53 SMAD4 MUC5AC MUC1 MLH1 KRT7
34 adenocarcinoma 28.4 TP53 SMAD4 MUC1 MSH6 MSH2 MLH1
35 lynch syndrome 28.3 TP53 SMAD4 PMS2 MUTYH MSH6 MSH2
36 adenoma 28.2 TP53 SST SMAD4 MUTYH MUC6 MUC5AC
37 pancreatic cancer 27.3 TP53 SST SMAD4 SCT MUC6 MUC5AC
38 gastric cancer 27.3 TP53 SMAD4 MUTYH MUC6 MUC5AC MUC1
39 ovary neuroendocrine neoplasm 10.5 KRT7 CDX2
40 anal canal paget's disease 10.5 KRT7 CDX2
41 gastric signet ring cell adenocarcinoma 10.4 KRT7 CDX2
42 bartholin's gland disease 10.4 KRT7 CDX2
43 scrotum paget's disease 10.4 MUC1 KRT7
44 bartholin's gland carcinoma 10.4 KRT7 CDX2
45 thymic neuroendocrine tumor 10.4 MEN1 HRAS
46 cervical mucinous adenocarcinoma 10.4 MUC6 KRT7
47 cystitis cystica 10.4 KRT7 CDX2
48 gallbladder signet ring cell adenocarcinoma 10.4 MUC1 KRT7
49 hepatic flexure cancer 10.4 KRAS HRAS
50 ethmoid sinus cancer 10.4 HRAS CDX2

Comorbidity relations with Duodenum Cancer via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Cholestasis
Deficiency Anemia Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Duodenum Cancer:



Diseases related to Duodenum Cancer

Symptoms & Phenotypes for Duodenum Cancer

UMLS symptoms related to Duodenum Cancer:


abdominal pain

GenomeRNAi Phenotypes related to Duodenum Cancer according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.5 HRAS KRAS KRT7 MEN1 MUC5AC MUTYH
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.32 MLH1
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.32 MLH1 TP53
4 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-3 9.32 MEN1 MLH1 MSH2 MSH6 MUTYH PMS2

MGI Mouse Phenotypes related to Duodenum Cancer:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.93 CDX2 GAST HRAS KRAS MEN1 MLH1
2 homeostasis/metabolism MP:0005376 9.83 CDX2 GAST HRAS KRAS KRT7 MEN1
3 neoplasm MP:0002006 9.4 CDX2 GAST HRAS KRAS MEN1 MLH1

Drugs & Therapeutics for Duodenum Cancer

Drugs for Duodenum Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 38)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Celecoxib Approved, Investigational Phase 2, Phase 3 169590-42-5 2662
2
Ursodeoxycholic acid Approved, Investigational Phase 2, Phase 3 128-13-2 31401
3 Gastrointestinal Agents Phase 2, Phase 3
4 Analgesics, Non-Narcotic Phase 2, Phase 3
5 Cyclooxygenase Inhibitors Phase 2, Phase 3
6 Cyclooxygenase 2 Inhibitors Phase 2, Phase 3
7 Analgesics Phase 2, Phase 3
8 Antirheumatic Agents Phase 2, Phase 3
9 Anti-Inflammatory Agents Phase 2, Phase 3
10 Anti-Inflammatory Agents, Non-Steroidal Phase 2, Phase 3
11
Heparin Approved, Investigational Phase 2 9005-49-6 772 9812414
12
Dalteparin Approved Phase 2 9005-49-6
13
Apixaban Approved Phase 2 503612-47-3 10182969
14
Rivaroxaban Approved Phase 2 366789-02-8
15
Tinzaparin Approved Phase 2 9041-08-1, 9005-49-6 25244225
16 Anticoagulants Phase 2
17 Serine Proteinase Inhibitors Phase 2
18 Antithrombin III Phase 2
19 Fibrinolytic Agents Phase 2
20 Heparin, Low-Molecular-Weight Phase 2
21 Factor Xa Inhibitors Phase 2
22
protease inhibitors Phase 2
23 calcium heparin Phase 2
24 Antithrombins Phase 2
25 HIV Protease Inhibitors Phase 2
26
Serine Investigational, Nutraceutical Phase 2 56-45-1 5951
27
Irinotecan Approved, Investigational Phase 1 100286-90-6, 97682-44-5 60838
28 topoisomerase I inhibitors Phase 1
29
Glucagon Approved 16941-32-5
30
Octreotide Approved, Investigational 83150-76-9 6400441 383414
31
Somatostatin Approved, Investigational 38916-34-6, 51110-01-1 53481605
32 Liver Extracts
33 Glucagon-Like Peptide 1
34 Hormones
35 Antineoplastic Agents, Hormonal
36 Antibiotics, Antitubercular
37 Anti-Bacterial Agents
38 Anti-Infective Agents

Interventional clinical trials:

(show all 30)
# Name Status NCT ID Phase Drugs
1 Early Oral Versus Enteral Nutrition After Pancreatoduodenectomy for Periampullary Tumors: a Prospective, Randomized, Controlled Clinical Trial Unknown status NCT01642875 Phase 4
2 Prevention of Progression of Duodenal Adenomas to Cancer in Patients With Familial Adenomatous Polyposis (FAP) Completed NCT00808743 Phase 2, Phase 3 Celecoxib;Ursodeoxycholic acid;Placebo
3 A Prospective Randomized Clinical Trial of Two Surgical Techniques for Pancreaticojejunostomy in Patients Undergoing Pancreaticoduodenectomy: Nonstented Stump-closed vs Duct-to-Mucosa Pancreaticojejunostomy Completed NCT01731821 Phase 3
4 A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism in Patients With Advanced Upper Gastrointestinal, Hepatobiliary and Pancreatic Cancer: PRIORITY Recruiting NCT03139487 Phase 2 Rivaroxaban;Dalteparin;apixaban
5 Endoscopic Strategy Versus Surgical by Pass in Nonresectable Periampullary Cancer Withdrawn NCT00487851 Phase 2
6 Phase I Study of Irinotecan Administered as a Continuous Infusion and Radiation Therapy for Upper Gastrointestinal Cancers Completed NCT00183846 Phase 1 irinotecan
7 Endoscopic Resection: A Retrospective and Prospective Multicenter Registry Unknown status NCT03065257
8 Proximal Roux-en-y Gastrojejunal Anastomosis on Delayed Gastric Emptying After Pylorus-resecting Pancreaticoduodenectomy: A Randomized Controlled Trial Unknown status NCT02954302
9 Endoscopic Retrograde Cholangiopancreatography, Endoscopic Ultrasound and Interventional Endoscopy in Pancreatico-biliary, Gastrointestinal and Esophageal Disorders Unknown status NCT01438385
10 A Prospective Randomized Controlled Trial Comparing Isolated Roux-en-Y Reconstruction With Billroth-II-type Reconstruction After Pancreaticoduodenectomy Unknown status NCT00915863
11 Essai de faisabilité Pour Une Endomicroscopie Robotisée Dans la redéfinition Des Stratégies d&Apos;ExérèsE Completed NCT02312167
12 Side-to-side Duodenojejunostomy After Resection of Third and Fourth Duodenal Part With Pancreatic Preservation Completed NCT04151394
13 1997-2011 Duodenal Cancer Analysis in Southern Denmark Completed NCT01661049
14 Colonization of Bile Ducts and Postoperative Infectious Complications of Pancreaticoduodenectomies Completed NCT03525067
15 The Effect of Satiety Gut Hormone Modulation on Appetitive Drive After Upper Gastrointestinal Surgery Completed NCT02381249 Octreotide;Placebo
16 Effect of Enteral Nutrition on Delayed Gastric Emptying After Pancreaticoduodenectomy: A Prospective, Randomized Controlled Trial Completed NCT03150615
17 Multicenter, Prospective Randomized Controlled Trial Evaluating Postoperative Oral Nutritional Supplementation for the Patients Who Received Major Gastrointestinal Surgery Completed NCT01838109
18 Prospective, Randomized, and Controlled Trial That Lost Stent Versus External Stent of Pancreaticojejunostomy After Pancreaticoduodenectomy Completed NCT00628186
19 Randomized Controlled Trial on the Evaluation of Pylorus-ring in Pancreaticoduodenectomy Completed NCT00639314
20 Endoscopic Evaluation of Duodenal Polyposis in Patients With Familial Adenomatous Polyposis (FAP) - a Single Center Prospective Validation of the Spigelman Classification Completed NCT03346980
21 Outcome After Surgical Treatment of Gastrointestinal Stromal Tumors in the Second Part of Duodenum: Is Localized Resection Appropriate? Completed NCT04487002
22 Monitoring of patIents With Microdialysis Following Pancreaticoduodenectomy - a Randomized Controlled Trial. THE MINIMUM STUDY Recruiting NCT03631173
23 Magnetic Compressive Anastomosis for Biliojejunostomy and Pancreaticojejunostomy During Whipple's Procedure: a Prospective Case-control Study Recruiting NCT03792048
24 Prevalence of Sub-epithelial Lesions Among Patients Undergoing EGDs in Egypt Recruiting NCT04622098
25 Quebec Pancreas Cancer Study Recruiting NCT04104230
26 Integrated Cancer Repository for Cancer Research Recruiting NCT02012699
27 Preoperative Hyperbaric Oxygen Therapy (HBOT) vs. Non Preoperative HBOT in Patients Undergoing Pancreaticoduodenectomy for Premalignant, and Malignant Tumors of the Common Bile Duct, Periampullary and Duodenum Enrolling by invitation NCT02575014 Preoperative hyperbaric oxygen
28 Retrospective Study of Efficacy and Safety of the Endoscopic Removal of Cancerous and Precancerous Lesions of the Upper and Lower Digestive Tract Not yet recruiting NCT04780256
29 A Randomized Trial of Two Surgical Techniques for Pancreaticojejunostomy in Patients Undergoing Pancreaticoduodenectomy Terminated NCT00359320
30 Evaluation of the Use of Intra-operative Molecular Imaging With BetaScope and in Vitro Measurement With LightPath Specimen Analyser Devices in Gastrointestinal Tumour Surgery Withdrawn NCT02446379 The marketed product 2-5 MBq/kg 18F-fluorodeoxyglucose

Search NIH Clinical Center for Duodenum Cancer

Cochrane evidence based reviews: duodenal neoplasms

Genetic Tests for Duodenum Cancer

Anatomical Context for Duodenum Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Duodenum Cancer:

19
Beginning Section Of The Small Intestine

MalaCards organs/tissues related to Duodenum Cancer:

40
Small Intestine, Pancreas, Lymph Node, Liver, Colon, Kidney, Brain

Publications for Duodenum Cancer

Articles related to Duodenum Cancer:

(show top 50) (show all 398)
# Title Authors PMID Year
1
Risks, Benefits, and Effects on Management for Biopsy of the Papilla in Patients With Familial Adenomatous Polyposis. 61
32492482 2021
2
Real-world data on microsatellite instability status in various unresectable or metastatic solid tumors. 61
33403729 2021
3
Preoperative misdiagnosis of pancreatic and periampullary cancer in patients undergoing pancreatoduodenectomy: A multicentre retrospective cohort study. 61
33745791 2021
4
Mucosal duodenal cancer originating from a Peutz-Jeghers polyp: Endocytoscopic features. 61
33687112 2021
5
The prevalence of micronutrient deficiency in patients with suspected pancreatico-biliary malignancy: Results from a specialist Hepato-Biliary and Pancreatic unit. 61
33775486 2021
6
[A Case of Duodenal Adenocarcinoma in the Third Portion Treated with Partial Duodenectomy]. 61
33597385 2021
7
Magnesium-induced ketamine toxicity. 61
33593869 2021
8
Endoscopic management of duodenal adenomas in patients with familial adenomatous polyposis. 61
32535190 2021
9
The real-world data on microsatellite instability status in various unresectable or metastatic solid tumors. 61
33426756 2021
10
Metachronous primary colon and periampullary duodenal cancer: A case report. 61
33546078 2021
11
Endoscopic Full-Thickness Resection in a Patient With Early Duodenal Cancer. 61
33324707 2020
12
Comparative Analysis of Outcomes and Clinicopathological Characteristics of Duodenal Adenocarcinoma: A SEER Analysis. 61
33073637 2020
13
Endocytoscopic observation with methylene blue staining for duodenal neoplasms associated with familial adenomatous polyposis. 61
33154543 2020
14
Survival outcomes after surgical management of sporadic or familial adenomatous polyposis associated duodenal cancer. 61
33124067 2020
15
Dye chromoendoscopy leads to a higher adenoma detection in the duodenum and stomach in patients with familial adenomatous polyposis. 61
33015332 2020
16
Surgery for colloid carcinoma of the pancreas with portal vein tumor thrombus: a case report. 61
33001318 2020
17
Pedicled jejunal flap reconstruction for partial duodenectomy: a report of two cases. 61
33072250 2020
18
Natural orifice specimen extraction surgery in laparoscopic pancreaticoduodenectomy: A single-center case series. 61
32805429 2020
19
The incidence of non-ampullary duodenal cancer in Japan: The first analysis of a national cancer registry. 61
33002211 2020
20
Microbiome Dysbiosis and Predominant Bacterial Species as Human Cancer Biomarkers. 61
31605288 2020
21
Endoscopic Surveillance of Duodenal Polyposis After Total Gastrectomy in Familial Adenomatous Polyposis. 61
32903873 2020
22
[Current Status and Future Perspectives of the Treatment of Rare Cancer-The Treatment Guidelines for Duodenal Cancer]. 61
32668841 2020
23
Isoperistaltic Jejunal Loop Interposition after Total Gastrectomy for Gastric Cancer in Patients with Familial Adenomatous Polyposis. 61
32596005 2020
24
[A Case of Duodenal Cancer with Advanced Lymph Node Metastasis Treated with mFOLFOX6 Preoperative Chemotherapy]. 61
32389965 2020
25
Jejunogastric intussusception after Whipple procedure with B-II reconstruction: a case report. 61
32276605 2020
26
Circulating Tumor Cells are an Independent Predictor of Shorter Survival in Patients Undergoing Resection for Pancreatic and Periampullary Adenocarcinoma. 61
30216219 2020
27
Laparoscopic pancreaticoduodenectomy for periampullary tumors: lessons learned from 500 consecutive patients in a single center. 61
31214805 2020
28
[A Case of Emergency Pancreaticoduodenectomy for Tumor Bleeding in Duodenal Cancer with Multiple Liver Metastases]. 61
32381874 2020
29
Hybrid laparoscopic pancreas-preserving subtotal duodenectomy for suspected early duodenal cancer: A case report. 61
33395821 2020
30
Endocytoscopic Observation of Non-Ampullary Mucosal Duodenal Cancer. 61
32355485 2020
31
Candidal Prosthetic Hip Infection in a Patient with Previous Candidal Sepsis - A Case Report. 61
33268609 2020
32
Potential effects of umami ingredients on human health: Pros and cons. 61
31272187 2020
33
Efficacy of Full-Spectrum Endoscopy to Visualize the Major Duodenal Papilla in Patients with Familial Adenomatous Polyposis. 61
31311010 2020
34
A Support Vector Machine Model Predicting the Risk of Duodenal Cancer in Patients with Familial Adenomatous Polyposis at the Transcript Levels. 61
32626748 2020
35
A Study of Clinical Presentation and Management of Malignant Gastric Outlet Obstruction (Northeast India-Based Single-Centre Experience). 61
31857759 2019
36
Comparison of pancreas-sparing duodenectomy (PSD) and pancreatoduodenectomy (PD) for the management of duodenal polyposis syndromes. 61
31474487 2019
37
Cholecystoduodenal fistula caused by aggressive mucinous gallbladder carcinoma with a porcelain gallbladder. 61
30919282 2019
38
Krukenburg Tumors Arising from Rare Primary Sites: Role of 18F-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography in Management and Outcome. 61
31579221 2019
39
Surgical management of familial adenomatous polyposis: pancreas-sparing duodenectomy or pancreaticoduodenectomy (Whipple procedure). 61
31257898 2019
40
Gene Expression Changes Accompanying the Duodenal Adenoma-Carcinoma Sequence in Familial Adenomatous Polyposis. 61
31211760 2019
41
Tumour stage and resection margin status are independent survival factors following partial pancreatoduodenectomy for duodenal adenocarcinoma. 61
30972486 2019
42
Functional Expression of Mucin1 in Human Duodenal Adenocarcinoma. 61
30763811 2019
43
Superficial non-ampullary duodenal cancer identified by small-bowel capsule endoscopy: a case report (with video). 61
30259299 2019
44
[Clinicopathological Study of 15 Cases of Primary Duodenal Cancer]. 61
30914558 2019
45
Spigelman stage IV duodenal polyposis does not precede most duodenal cancer cases in patients with familial adenomatous polyposis. 61
30081000 2019
46
Challenges and pitfalls of investigating duodenal cancer in patients with familial adenomatous polyposis. 61
30665532 2019
47
[Peutz-Jeghers syndrome and cancer:a retrospective study in 14 Japanese patients with Peutz-Jeghers syndrome]. 61
31827041 2019
48
Mushroom polysaccharide lentinan for treating different types of cancers: A review of 12 years clinical studies in China. 61
31030752 2019
49
Possible involvement of Enterococcus infection in the pathogenesis of chronic pancreatitis and cancer. 61
30401562 2018
50
[A Case of Early Duodenal Cancer with Lymph Node Involvement Confirmed by Laparoscopic Lymph Node Sampling]. 61
30692312 2018

Variations for Duodenum Cancer

ClinVar genetic disease variations for Duodenum Cancer:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 APC NM_000038.6(APC):c.2558A>G (p.Glu853Gly) SNV Uncertain significance 559955 rs1554084263 GRCh37: 5:112173849-112173849
GRCh38: 5:112838152-112838152
2 APC NM_000038.6(APC):c.1984C>A (p.Leu662Ile) SNV Uncertain significance 232098 rs756859993 GRCh37: 5:112173275-112173275
GRCh38: 5:112837578-112837578

Expression for Duodenum Cancer

Search GEO for disease gene expression data for Duodenum Cancer.

Pathways for Duodenum Cancer

Pathways related to Duodenum Cancer according to GeneCards Suite gene sharing:

(show all 23)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.82 TP53 MSH6 MSH2 MLH1 KRAS HRAS
2
Show member pathways
12.66 TP53 SMAD4 MSH6 MSH2 MLH1 KRAS
3
Show member pathways
12.6 TP53 SMAD4 MLH1 KRAS HRAS CDX2
4 12.53 TP53 SMAD4 MSH6 MSH2 MLH1 KRAS
5 12.41 TP53 MUTYH MSH6 MSH2 MLH1
6
Show member pathways
12.39 TP53 SMAD4 MUC1 KRAS HRAS
7
Show member pathways
12.29 MUC6 MUC5AC MUC1 KRAS HRAS
8 12.23 TP53 SMAD4 KRAS HRAS
9 11.97 TP53 PMS2 MSH2 MLH1
10 11.91 TP53 SMAD4 MSH6 MSH2 KRAS
11 11.86 TP53 SMAD4 KRAS HRAS
12
Show member pathways
11.71 TP53 MSH6 MSH2
13
Show member pathways
11.71 PMS2 MSH6 MSH2 MLH1
14 11.64 TP53 KRAS HRAS
15 11.62 TP53 KRAS HRAS
16 11.59 TP53 KRAS HRAS
17 11.57 TP53 MSH6 MSH2 MLH1
18 11.41 TP53 MSH6 MSH2
19
Show member pathways
11.34 TP53 MSH2 MLH1
20 11.32 TP53 SMAD4 MSH6 MSH2 MLH1 KRAS
21 11.16 SMAD4 KRAS HRAS
22 10.72 PMS2 MSH6 MSH2 MLH1
23 10.18 SCT MUC6 GAST

GO Terms for Duodenum Cancer

Cellular components related to Duodenum Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MutLalpha complex GO:0032389 9.16 PMS2 MLH1
2 MutSalpha complex GO:0032301 8.96 MSH6 MSH2
3 mismatch repair complex GO:0032300 8.92 PMS2 MSH6 MSH2 MLH1

Biological processes related to Duodenum Cancer according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.98 TP53 SST SMAD4 MEN1 HRAS
2 DNA repair GO:0006281 9.88 PMS2 MUTYH MSH6 MSH2 MLH1 MEN1
3 cellular response to DNA damage stimulus GO:0006974 9.87 TP53 PMS2 MUTYH MSH6 MSH2 MLH1
4 Ras protein signal transduction GO:0007265 9.77 TP53 KRAS HRAS
5 O-glycan processing GO:0016266 9.73 MUC6 MUC5AC MUC1
6 response to UV GO:0009411 9.71 TP53 MSH6 MEN1
7 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.67 MSH6 MSH2 MLH1
8 intrinsic apoptotic signaling pathway GO:0097193 9.65 TP53 MSH6 HRAS
9 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.65 MUC6 MUC5AC MUC1 KRAS HRAS
10 response to transforming growth factor beta GO:0071559 9.61 SMAD4 MEN1
11 determination of adult lifespan GO:0008340 9.61 TP53 MSH6 MSH2
12 positive regulation of isotype switching to IgG isotypes GO:0048304 9.59 MSH2 MLH1
13 response to isolation stress GO:0035900 9.58 KRAS HRAS
14 positive regulation of transcription from RNA polymerase II promoter in response to stress GO:0036003 9.57 TP53 MUC1
15 positive regulation of helicase activity GO:0051096 9.55 MSH6 MSH2
16 isotype switching GO:0045190 9.54 MSH6 MSH2 MLH1
17 positive regulation of isotype switching to IgA isotypes GO:0048298 9.52 MSH2 MLH1
18 maintenance of DNA repeat elements GO:0043570 9.51 MSH6 MSH2
19 somatic recombination of immunoglobulin genes involved in immune response GO:0002204 9.46 MSH2 MLH1
20 somatic recombination of immunoglobulin gene segments GO:0016447 9.33 MSH6 MSH2 MLH1
21 somatic hypermutation of immunoglobulin genes GO:0016446 9.26 PMS2 MSH6 MSH2 MLH1
22 mismatch repair GO:0006298 9.02 PMS2 MUTYH MSH6 MSH2 MLH1

Molecular functions related to Duodenum Cancer according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.49 TP53 SST SMAD4 SCT PMS2 MUTYH
2 chromatin binding GO:0003682 9.88 TP53 SMAD4 MSH6 MSH2 MLH1 MEN1
3 ATPase activity GO:0016887 9.8 PMS2 MSH6 MSH2 MLH1
4 double-stranded DNA binding GO:0003690 9.78 MSH6 MSH2 MEN1 CDX2
5 four-way junction DNA binding GO:0000400 9.54 MSH6 MSH2 MEN1
6 MutSalpha complex binding GO:0032407 9.5 PMS2 MUTYH MLH1
7 single guanine insertion binding GO:0032142 9.46 MSH6 MSH2
8 single thymine insertion binding GO:0032143 9.43 MSH6 MSH2
9 MutLalpha complex binding GO:0032405 9.43 MUTYH MSH6 MSH2
10 oxidized purine DNA binding GO:0032357 9.33 MUTYH MSH6 MSH2
11 guanine/thymine mispair binding GO:0032137 9.13 MSH6 MSH2 MLH1
12 mismatched DNA binding GO:0030983 8.92 PMS2 MSH6 MSH2 MLH1

Sources for Duodenum Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....